ESR projects

Research project

DNA methylation as determinant of myelodysplastic syndromes treatment with hypomethylating agents (WP2)

Rationale and objectives

Hypomethylating agents (HMAs) are the current best care for myelodysplastic syndromes (MDS) patients not eligible for transplantation. However, treatment success is partial and we are lacking biomarkers and combinatorial drug targets.

See more

The project's objectives are:

• To characterize evolution of DNA methylation patterns in bone marrow samples during HMA therapy.

• To correlate DNA methylation patterns at the population and single-cell level with response and therapy failure.

• To study the potential synergy of natural and experimental genetic perturbation of chromatin modifiers with HMAs.

See less

Envisioned secondments

Josep Carreras Leukaemia Research Institute (Spain, 3 months), MLL Munich Leukemia Laboratory (Germany, 2 months).

PhD programme

PhD in Genetics, Oncology and Clinical Medicine, UniFi, Italy.